

Meet The Professors: Clinical Investigators Consult on Challenging Real Cases of Patients with Prostate Cancer



Co-Chairs

Daniel J George, MD

Neil Love, MD

Faculty

Stephen J Freedland, MD

Philip Kantoff, MD

William K Oh, MD

A Oliver Sartor, MD

Cosponsored by Duke University School
of Medicine and Research To Practice.

 **Duke University**
School of Medicine
Research
To Practice®



Subscribe to Podcasts or download
MP3s of this program at
ResearchToPractice.com/GUCancers



Meet The Professors: Clinical Investigators Consult on Challenging Real Cases of Patients with Prostate Cancer

An Audio-Based Continuing Medical Education Activity

STATEMENT OF NEED

Cancer of the genitourinary system affects hundreds of thousands of individuals within the United States each year and comprises almost 30 percent of all newly diagnosed tumors in humans. Although a diverse array of distinct diseases, tumors of the prostate are among the most prevalent and thus the topic of extensive ongoing clinical research. To this end, the management of prostate cancer is continuously in a state of evolution, necessitating rapid and consistent access to learning opportunities for oncologists, urologists and other cancer clinicians who provide care for these patients. These proceedings from an interactive case-based meeting held during the 2011 Genitourinary Cancers Symposium will offer medical professionals a multifaceted educational experience focused specifically on the current treatment of prostate cancer.

TARGET AUDIENCE

This activity is intended for medical oncologists, radiation oncologists, urologists and other healthcare providers involved in the treatment of prostate cancer.

LEARNING OBJECTIVES

- Use evidence-based molecular and clinical factors to refine prognosis and treatment recommendations for patients with prostate cancer (PC).
- Apply case-based learning to the best-practice delivery of systemic therapy for patients with locally advanced and metastatic PC.
- Educate patients with castration-resistant PC (CRPC) about the effects of docetaxel and cabazitaxel on quality and quantity of life.
- Counsel patients about the efficacy and safety of immunotherapy for patients with asymptomatic and symptomatic CRPC.
- Explore the emerging data and active research evaluating novel agents in the setting of advanced PC, and discuss the biologic basis for their clinical activity.
- Communicate the availability of ongoing clinical trial participation to appropriately selected patients with PC.

ACCREDITATION STATEMENT

The Duke University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

The Duke University School of Medicine designates this educational activity for a maximum of 1.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO RECEIVE CREDIT

This CME activity contains an audio component. To receive credit, the participant should review the CME information, listen to the CD and complete the Post-test and Educational Assessment and Credit Form located in the back of this booklet or on our website at ResearchToPractice.com/GUCancers/CME.

This CME activity is supported by educational grants from Dendreon Corporation and sanofi aventis U.S.

Unapproved Use Disclosure

Duke School of Medicine requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Faculty will not be discussing information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

Last review date: June 20, 2011; Release date: June 20, 2011; Expiration date: June 19, 2012

If you would like to discontinue your complimentary subscription to *Prostate Cancer Update*, please email us at Info@ResearchToPractice.com, call us at (800) 648-8654 or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.

CO-CHAIRS

Daniel J George, MD

Associate Professor of Medicine and Surgery
Director of Genitourinary Oncology
Duke Medical Center
Durham, North Carolina

Neil Love, MD

President
Research To Practice
Miami, Florida

FACULTY AFFILIATIONS

Stephen J Freedland, MD

Attending Physician, Durham VA Medical Center
Associate Professor of Urology and Pathology
Duke Prostate Center
Duke University School of Medicine
Durham, North Carolina

Philip Kantoff, MD

Chief Clinical Research Officer; Chief, Division of Solid Tumor Oncology; Director of the Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute; Professor of Medicine
Harvard Medical School
Boston, Massachusetts

William K Oh, MD

Chief, Division of Hematology and Medical Oncology; Professor of Medicine and Urology
Ezra M Greenspan MD Professor in Clinical Cancer Therapeutics, Mount Sinai School of Medicine; Associate Director of Clinical Research, The Tisch Cancer Institute
New York, New York

A Oliver Sartor, MD

Medical Director, Tulane Cancer Center
Piltz Endowed Professor of Cancer Research
Professor of Medicine and Urology
Tulane Medical School
New Orleans, Louisiana

TREATING ONCOLOGISTS

Andrew J Armstrong, MD, ScM

Assistant Professor of Medicine and Surgery
Duke Cancer Institute and the Duke Prostate Center
Departments of Medicine and Surgery
Divisions of Medical Oncology and Urology
Durham, North Carolina

Philip T Glynn, MD

Director of Oncology
Noble Hospital
Assistant Clinical Professor
Tufts University School of Medicine
Springfield, Massachusetts

Manjesh Lingamurthy, MD

Hematology/Oncology
Michael and Dianne Bienes
Comprehensive Cancer Center
Holy Cross Hospital
Fort Lauderdale, Florida

Erik J Rupard, MD, LTC

Chief, Hematology-Oncology Service
Dwight David Eisenhower Army Medical Center
Assistant Professor at Medical College of Georgia; Assistant Professor at Uniformed Services University of the Health Sciences
Ft Gordon, Georgia

RESOLUTION OF CONFLICTS OF INTEREST

In accordance with the ACCME Standards for Commercial Support of CME, the Duke University School of Medicine implemented mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.

FACULTY DISCLOSURE — The following speakers and/or planning committee members have indicated they have no relationship(s) with industry to disclose relative to the content of the CME activity: **Drs Glynn, Lingamurthy, Love and Rupard.**

The following speakers and/or planning committee members have indicated that they have relationship(s) with industry to disclose: **Dr Armstrong** — Advisory Board Member: Active Biotech, Bristol-Myers Squibb; Consultant: Active Biotech, Amgen, Dendreon; Principal Investigator: Active Biotech, Bristol-Myers Squibb, Dendreon, Eli Lilly, Imclone, Medivation, Novartis, Pfizer, sanofi aventis; **Dr Freedland** — Advisory Board Member: Amgen, Astra Zeneca, Bayer Pharmaceuticals, Dendreon, GlaxoSmithKline, Johnson & Johnson; **Speaker:** Amgen, Astra Zeneca, Johnson & Johnson. **Dr George** — Advisory Board Member: sanofi aventis; Consultant: Dendreon, Genentech, Novartis, Pfizer; Principal Investigator: Bristol-Myers Squibb, Dendreon, GlaxoSmith-Kline, Johnson & Johnson, Novartis, Pfizer; **Speaker:** Dendreon, Genentech, Novartis, Pfizer, sanofi aventis. **Dr Kantoff** — Advisory Board Member: BIND; Consultant: Amgen, Bellicum, BI Immunotherapeutics, Genentech, Johnson & Johnson, Ortho Biotech, Pfizer, Tokai. **Dr Oh** — Advisory Board Member: Bellicum, sanofi aventis; Consultant: Amgen, Genentech, Johnson & Johnson, Pfizer; Principal Investigator: Millennium. **Dr Sartor** — Consultant: Amgen, Astra Zeneca, Johnson & Johnson; Principal Investigator: Astra Zeneca, GlaxoSmithKline, Johnson & Johnson, sanofi aventis.

STAFF AND CONTENT VALIDATION REVIEWER

DISCLOSURES — The staff involved in the planning and content development of this activity have reported no relevant financial relationships with commercial interests.

DISCLAIMER

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Meet The Professors: Clinical Investigators Consult on Challenging Real Cases of Patients with Prostate Cancer

QUESTIONS (PLEASE CIRCLE ANSWER):

1. A PSA doubling time of less than three months is associated with an increased risk of prostate cancer-specific mortality in patients _____.
 - a. After radical prostatectomy
 - b. After radiation therapy
 - c. Both a and b
2. A recently reported study in the *Journal of Clinical Oncology* demonstrated that three or more hours per week of physical activity in men with prostate cancer could substantially improve prostate cancer-specific survival.
 - a. True
 - b. False
3. Sipuleucel-T is a(n) _____.
 - a. Chemotherapy agent
 - b. Targeted small-molecule tyrosine kinase inhibitor
 - c. E coli-derived antibody to PSA
 - d. Autologous cellular immunotherapy agent
4. In the IMPACT trial, sipuleucel-T demonstrated improvement in _____ among patients with CRPC.
 - a. PSA response
 - b. Progression-free survival
 - c. Overall survival
 - d. All of the above
5. For which of the following prostate cancer subtypes is sipuleucel-T clinically indicated?
 - a. Asymptomatic or minimally symptomatic metastatic CRPC
 - b. Moderately symptomatic metastatic CRPC
 - c. Severely symptomatic metastatic CRPC
6. In the TROPIC trial, the novel taxane cabazitaxel in combination with prednisone demonstrated a significant improvement in _____ compared to mitoxantrone/prednisone for patients with metastatic CRPC previously treated with docetaxel.
 - a. Overall survival
 - b. Progression-free survival
 - c. Both a and b
7. In the TROPIC trial, prophylactic growth factor support was not used and rates of febrile neutropenia were eight percent and one percent for cabazitaxel and mitoxantrone, respectively.
 - a. True
 - b. False
8. In a recent study presented at ESMO, abiraterone acetate administered to patients with metastatic prostate cancer who had experienced disease progression on docetaxel failed to show an overall survival advantage.
 - a. True
 - b. False
9. Approximately what percent of patients with symptomatic, metastatic CRPC are expected to experience pain reduction with chemotherapy?
 - a. None
 - b. 10 percent
 - c. >30 percent
10. Which of the following appear to predict response to docetaxel with or without carboplatin rechallenge in patients with docetaxel-refractory metastatic CRPC?
 - a. Prior response to docetaxel
 - b. Longer interval between treatment and re-treatment
 - c. Both a and b

Educational Assessment and Credit Form — Meet The Professors: Clinical Investigators Consult on Challenging Real Cases of Patients with Prostate Cancer

Please respond to the following learning objectives by circling the appropriate selection:

5 = Strongly agree 4 = Agree 3 = Neutral 2 = Disagree 1 = Strongly disagree N/A = Not applicable

As a result of this activity, I will be able to:

- Use evidence-based molecular and clinical factors to refine prognosis and treatment recommendations for patients with prostate cancer (PC). 5 4 3 2 1 N/A
- Apply case-based learning to the best-practice delivery of systemic therapy for patients with locally advanced and metastatic PC. 5 4 3 2 1 N/A
- Educate patients with castration-resistant PC (CRPC) about the effects of docetaxel and cabazitaxel on quality and quantity of life. 5 4 3 2 1 N/A
- Counsel patients about the efficacy and safety of immunotherapy for patients with asymptomatic and symptomatic CRPC. 5 4 3 2 1 N/A
- Explore the emerging data and active research evaluating novel agents in the setting of advanced PC, and discuss the biologic basis for their clinical activity. 5 4 3 2 1 N/A
- Communicate the availability of ongoing clinical trial participation to appropriately selected patients with PC. 5 4 3 2 1 N/A

Please rate the projected impact of this activity on your knowledge, competence*, performance and patient outcomes¹:

This activity increased my knowledge	Yes	No	No change
This activity increased my competence	Yes	No	No change
This activity improved my performance	Yes	No	No change
This activity will improve my patient outcomes	Yes	No	No change

If yes to any of the above, please describe:

.....

Do you feel the activity was scientifically sound, free of commercial bias² or influence, balanced and objective?

- Yes No If no, please explain:

Please identify how you will change your practice as a result of completing this activity (select all that apply).

- This activity validated my current practice; no changes will be made
 - Create/revise protocols, policies and/or procedures
 - Change the management and/or treatment of my patients
 - Other (please explain):
-

Please indicate any barriers you perceive in implementing these changes.

- Cost
 - Lack of experience
 - Lack of opportunity (patients)
 - Lack of resources (equipment)
 - Lack of administrative support
 - Lack of time to assess/counsel patients
 - Reimbursement/insurance issues
 - Patient compliance issues
 - Lack of consensus or professional guidelines
 - No barriers
 - Other (please specify):
-

Will you attempt to address these barriers in order to implement changes in your competence, performance and/or patients' outcomes?

- N/A
- No — Why not?
- Yes — How?

** Competence is defined as the ability to apply knowledge, skills and judgment in practice (knowing how to do something); ¹ The Accreditation Council for CME requires us to analyze changes in learners' competence, performance or patient outcomes; ² Commercial bias is defined as a personal judgement in favor of a specific product or service of a commercial interest.*

EDUCATIONAL ASSESSMENT AND CREDIT FORM (continued)

The content of this activity matched my current (or potential) scope of practice.

Yes No If no, please explain:

.....

Overall, were the speakers knowledgeable regarding the content?

Yes No If no, please explain:

.....

Describe any content that was exceptional:

.....

.....

Describe any content that did not meet your needs or expectations:

.....

.....

Please describe any clinical situations that you find difficult to manage or resolve that you would like to see addressed in future educational activities:

.....

.....

.....

REQUEST FOR CREDIT — Please print clearly

The Duke University School of Medicine designates this educational activity for a maximum of 1.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

I certify my actual time spent to complete this educational activity to be _____ hour(s).

Signature: Date:

To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (919) 401-1213, or mail both to Duke University School of Medicine, Center for Educational Excellence, DukeCME, DCRI, 300 West Morgan Street, Suite 800, Box 104785, Durham, NC 27701. You may also complete the Post-test and Educational Assessment online at www.ResearchToPractice.com/GUCancers/CME.

Name: Specialty:

Professional Designation:

MD DO PharmD NP RN PA Other

Street Address: Box/Suite:

City, State, Zip:

Telephone: Fax:

Email:

GUCancers

Prostate Cancer™

U P D A T E

Co-Chair	Neil Love, MD
Managing Editor and CME Director	Kathryn Ault Ziel, PhD
Scientific Director	Richard Kaderman, PhD
Editorial	Clayton Campbell Gloria Kelly, PhD Jean Pak Margaret Peng
Creative Manager	Fernando Rendina
Graphic Designers	Jessica Benitez Jason Cunnius Tamara Dabney Silvana Izquierdo Deepti Nath
Copy Editing Manager	Kirsten Miller
Senior Production Editor	Aura Herrmann
Copy Editors	Margo Harris David Hill Rosemary Hulce Pat Morrissey/Havlin Alexis Oneca Carol Peschke
Production Manager	Tracy Potter
Audio Production	Frank Cesarano
Web Master	John Ribeiro
Multimedia Project Manager	Marie Philemon
Faculty Relations Manager	Melissa Molieri
Continuing Education Administrator for Nursing	Julia W Aucoin, DNS, RN-BC, CNE
Contact Information	Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: DrNeilLove@ResearchToPractice.com Email: CE@ResearchToPractice.com
For CME/CNE Information	

Copyright © 2011 Research To Practice. All rights reserved.

The compact disc, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the

newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

Prostate Cancer™

U P D A T E

Copyright © 2011 Research To Practice.
This CME activity is supported by educational grants
from Dendreon Corporation and sanofi aventis U.S.



Research
To Practice®

Cosponsored by the Duke University School of Medicine and Research To Practice.

Last review date: June 20, 2011
Release date: June 20, 2011
Expiration date: June 19, 2012
Estimated time to complete: 1.25 hours